1. Scrip
  2. >>Business
  3. >>Financing

Halda Raises $126m For First Clinical Trial Of Its RIPTAC Modality

Heterobifunctional Molecules From A PROTAC Pioneer

 
• By Mandy Jackson

Halda will take its first RIPTAC molecule into a clinical trial in prostate cancer, offering a new small molecule modality in an indication where patients and doctors prefer oral drugs.

Venture capital. Long term business investment
Halda has raised $202m to date • Source: Shutterstock

Induced proximity biology – bringing two molecules together to cause some kind of reaction – is in its heyday via the field of targeted protein degradation with proteolysis targeting chimera (PROTAC) therapeutics reaching previously undruggable targets. Now, Halda Therapeutics, with $126m in new venture capital financing, will conduct its first clinical trial of a novel induced proximity modality from a PROTAC pioneer.

Key Takeaways

  • Halda Therapeutics raised $126m to take its first RIPTAC, invented at the company and inspired by the research of PROTAC pioneer Craig Crews at Yale, into the clinic in 2025 in prostate cancer.

Halda founder and Yale University professor Craig Crews, founder of PROTAC developer Arvinas, Inc., wanted to inspire the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: CSL Restructuring Brings 15% Workforce Reduction, Vaccines Group Spinout

 
• By Mandy Jackson

Restructuring Edition: CSL Group will spin out CSL Seqirus as a standalone vaccines business as the parent company slims down. Some struggling companies are turning to investing in cryptocurrencies to create shareholder value.

Finance Watch: Did Mid-Summer Usher In A Mega-Round Comeback?

 
• By Mandy Jackson

Private Company Edition: Hatteras Venture Partners now has more than $900m under management. Also, in recent $100m-plus VC rounds, Strand Therapeutics raised a $153m series A, ARTBIO revealed a $132m series B and Minghui Pharmaceutical secured a $131m pre-IPO round.

Sarepta Sells Arrowhead Shares To Raise Cash, Pay Arrowhead

 
• By Mandy Jackson

Sarepta is in a cash crunch with sales of Elevidys slumping due to safety concerns and with financial commitments coming due, including debt repayments and milestone fees for its partner Arrowhead.

Finance Watch: OrbiMed’s New $1.86bn Fund Offers Financial Alternatives In Tough Market

 
• By Mandy Jackson

Public Company Edition: OrbiMed partners Carter Neild and Matthew Rizzo spoke with Scrip about the firm’s fifth royalty and credit fund. Also, Ligand sold $400m worth of notes, BridgeBio’s oncology spinout went public via SPAC merger and raised $261m and Assembly raised $175m.

More from Business

Boehringer Expands Eyecare Horizons With Palatin Collaboration

 
• By Andrew McConaghie

The German company already had four eye disease candidates in Phase II development and sees promise in Palatin’s novel melanocortin receptor modulators.

Egetis Eyes Swift US Submission For Emcitate

 
• By Kevin Grogan

The Sweden-based firm is set for talks with the FDA on the regulatory path for its MCT8 deficiency candidate.

Stock Watch: Pfizer Relights Q2 Earnings Season’s Fire

 
• By Andy Smith

Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.